EMA-话题@MedSci

#EMA#

580篇内容 | 2468人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, objectType=article, longId=168239, objectId=cddc168239ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cddc168239ad, replyNumber=0, likeNumber=69, createdTime=2019-06-14, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cddc168239ad, moduleTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cddc168239ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317512, encodeId=ef62131e512cf, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, objectType=article, longId=167495, objectId=7c2016e4958b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2016e4958b, replyNumber=0, likeNumber=76, createdTime=2019-06-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2016e4958b, moduleTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2016e4958b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317511, encodeId=5350131e5111e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物, objectType=article, longId=167494, objectId=f17c16e4943f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f17c16e4943f, replyNumber=0, likeNumber=60, createdTime=2019-06-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f17c16e4943f, moduleTitle=欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f17c16e4943f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317510, encodeId=de2f131e51022, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：沙班类抗凝药用于病态肥胖患者的效果和安全性是否可媲美华法林？, objectType=article, longId=166866, objectId=615816686665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615816686665, replyNumber=0, likeNumber=54, createdTime=2019-05-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615816686665, moduleTitle=Lancet Haemat：沙班类抗凝药用于病态肥胖患者的效果和安全性是否可媲美华法林？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=615816686665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317509, encodeId=5de7131e50987, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, objectType=article, longId=166117, objectId=2c7916611e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7916611e50, replyNumber=0, likeNumber=72, createdTime=2019-05-16, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7916611e50, moduleTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7916611e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=首发症状为颌下腺肿大的Castleman病超声表现1例, objectType=article, longId=165577, objectId=eaaa1655e786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaaa1655e786, replyNumber=0, likeNumber=66, createdTime=2019-05-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaaa1655e786, moduleTitle=首发症状为颌下腺肿大的Castleman病超声表现1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaaa1655e786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317507, encodeId=60e9131e5078f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, objectType=article, longId=165485, objectId=0adb1654850e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0adb1654850e, replyNumber=0, likeNumber=96, createdTime=2019-05-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0adb1654850e, moduleTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0adb1654850e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317506, encodeId=0edb131e50694, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=2019年美国神经病学学会年会：Teva将公布Fremanezumab的长期有效性和安全性数据, objectType=article, longId=165394, objectId=d1fe165394ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1fe165394ca, replyNumber=0, likeNumber=53, createdTime=2019-05-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1fe165394ca, moduleTitle=2019年美国神经病学学会年会：Teva将公布Fremanezumab的长期有效性和安全性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1fe165394ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317505, encodeId=c621131e5056a, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, objectType=article, longId=165382, objectId=9da8165382e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9da8165382e2, replyNumber=0, likeNumber=54, createdTime=2019-05-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9da8165382e2, moduleTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9da8165382e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317504, encodeId=e89b131e504a5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性, objectType=article, longId=165179, objectId=f5ca1651e910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ca1651e910, replyNumber=0, likeNumber=75, createdTime=2019-04-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ca1651e910, moduleTitle=Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ca1651e910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317503, encodeId=dffd131e5033c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：Emicizumab用于A型血友病出血预防, objectType=article, longId=164518, objectId=97741645181b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97741645181b, replyNumber=0, likeNumber=56, createdTime=2019-04-19, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97741645181b, moduleTitle=Lancet Haematol：Emicizumab用于A型血友病出血预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97741645181b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317502, encodeId=f0e0131e5020e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀, objectType=article, longId=164496, objectId=43d31644961f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d31644961f, replyNumber=0, likeNumber=88, createdTime=2019-04-19, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d31644961f, moduleTitle=JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d31644961f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317501, encodeId=335d131e501e5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理, objectType=article, longId=164440, objectId=fa3a164440b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa3a164440b4, replyNumber=0, likeNumber=57, createdTime=2019-04-18, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa3a164440b4, moduleTitle=Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa3a164440b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317500, encodeId=f3db131e50038, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, objectType=article, longId=164439, objectId=effa16443993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effa16443993, replyNumber=0, likeNumber=59, createdTime=2019-04-18, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effa16443993, moduleTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=effa16443993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317499, encodeId=1aaf131e49962, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, objectType=article, longId=164438, objectId=87fe1644385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fe1644385f, replyNumber=0, likeNumber=92, createdTime=2019-04-18, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fe1644385f, moduleTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fe1644385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317498, encodeId=c048131e49876, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, objectType=article, longId=163718, objectId=c32e163e1867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32e163e1867, replyNumber=0, likeNumber=58, createdTime=2019-04-07, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32e163e1867, moduleTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32e163e1867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317497, encodeId=9fa7131e497fc, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎, objectType=article, longId=163646, objectId=eaa016364694, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa016364694, replyNumber=0, likeNumber=78, createdTime=2019-04-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa016364694, moduleTitle=欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa016364694)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317496, encodeId=0b90131e496b9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=药明生物成为中国首家EMA GMP认证的生物制药公司, objectType=article, longId=162669, objectId=767816266971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=767816266971, replyNumber=0, likeNumber=69, createdTime=2019-03-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767816266971, moduleTitle=药明生物成为中国首家EMA GMP认证的生物制药公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=767816266971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317495, encodeId=5de2131e495bd, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测, objectType=article, longId=162296, objectId=bc66162296de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc66162296de, replyNumber=0, likeNumber=156, createdTime=2019-03-15, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc66162296de, moduleTitle=Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc66162296de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317494, encodeId=1904131e494a4, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA接受Idefirix治疗急性髓性白血病和Xospata用于肾移植的上市授权申请, objectType=article, longId=161655, objectId=1fb916165543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fb916165543, replyNumber=0, likeNumber=63, createdTime=2019-03-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fb916165543, moduleTitle=EMA接受Idefirix治疗急性髓性白血病和Xospata用于肾移植的上市授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fb916165543)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控

2019-06-14

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请

2019-06-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物

2019-06-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：沙班类抗凝药用于病态肥胖患者的效果和安全性是否可媲美华法林？

2019-05-28

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌

2019-05-16

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

首发症状为颌下腺肿大的Castleman病超声表现1例

2019-05-09

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征

2019-05-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

2019年美国神经病学学会年会：Teva将公布Fremanezumab的长期有效性和安全性数据

2019-05-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性

2019-05-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性

2019-04-30

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：Emicizumab用于A型血友病出血预防

2019-04-19

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀

2019-04-19

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理

2019-04-18

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效

2019-04-18

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估

2019-04-18

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证

2019-04-07

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎

2019-04-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

药明生物成为中国首家EMA GMP认证的生物制药公司

2019-03-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测

2019-03-15

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA接受Idefirix治疗急性髓性白血病和Xospata用于肾移植的上市授权申请

2019-03-06

科室
- - 订阅+
  - 更多科室
工具
服务